Plasminogen Activator Inhibitor Type 1 (PAI-1) A15T Gene Polymorphism Is Associated with Prognosis in Patients with EGFR Mutation Positive Pulmonary Adenocarcinoma |
Lim, Ju Eun
(Department of Internal Medicine, Hongik Hospital)
Park, Moo Suk (Division of Pulmonology, Department of Internal Medicine, The Institute of Chest Disease, Yonsei University College of Medicine) Kim, Eun Young (Division of Pulmonology, Department of Internal Medicine, The Institute of Chest Disease, Yonsei University College of Medicine) Jung, Ji Ye (Division of Pulmonology, Department of Internal Medicine, The Institute of Chest Disease, Yonsei University College of Medicine) Kang, Young Ae (Division of Pulmonology, Department of Internal Medicine, The Institute of Chest Disease, Yonsei University College of Medicine) Kim, Young Sam (Division of Pulmonology, Department of Internal Medicine, The Institute of Chest Disease, Yonsei University College of Medicine) Kim, Se Kyu (Division of Pulmonology, Department of Internal Medicine, The Institute of Chest Disease, Yonsei University College of Medicine) Shim, Hyo Sup (Department of Pathology, Department of Internal Medicine, Yonsei University College of Medicine) Cho, Byoung Chul (Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine) Chang, Joon (Division of Pulmonology, Department of Internal Medicine, The Institute of Chest Disease, Yonsei University College of Medicine) |
1 | Putila J, Remick SC, Guo NL. Combining clinical, pathological, and demographic factors refines prognosis of lung cancer: a population-based study. PLoS One 2011;6:e17493. DOI |
2 | Dai J, Jin G, Dong J, Chen Y, Xu L, Hu Z, et al. Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival. J Thorac Oncol 2010;5:1748-54. DOI |
3 | Togashi Y, Masago K, Fujita S, Kim YH, Sakamori Y, Hatachi Y, et al. Association of the transforming growth factor ss1 promoter polymorphism, C-509T, with smoking status and survival in advanced non-small cell lung cancer. Oncol Rep 2011;25:377-82. |
4 | Minamiya Y, Miura M, Hinai Y, Saito H, Ito M, Ono T, et al. Transforming growth factor-beta1 29T>C genetic polymorphism is associated with lymph node metastasis in patients with adenocarcinoma of the lung. Tumour Biol 2010;31:437- 41. DOI |
5 | Niu X, Chen Z, Shen S, Liu Y, Zhou D, Zhang J, et al. Association of the CHRNA3 locus with lung cancer risk and prognosis in Chinese Han population. J Thorac Oncol 2010;5:658-66. DOI |
6 | Horgan AM, Yang B, Azad AK, Amir E, John T, Cescon DW, et al. Pharmacogenetic and germline prognostic markers of lung cancer. J Thorac Oncol 2011;6:296-304. DOI |
7 | Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000;57:25-40. DOI |
8 | Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Kolk A, et al. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity: clinical relevance and prognostic value. J Craniomaxillofac Surg 2005;33:191-6. DOI |
9 | Duffy MJ. The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 2004;10:39-49. DOI |
10 | Duffy MJ, McGowan PM, Gallagher WM. Cancer invasion and metastasis: changing views. J Pathol 2008;214:283-93. DOI |
11 | Binder BR, Mihaly J. The plasminogen activator inhibitor "paradox" in cancer. Immunol Lett 2008;118:116-24. DOI |
12 | Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994;54:4671-5. |
13 | Bouchard L, Mauriege P, Vohl MC, Bouchard C, Perusse L. Plasminogen-activator inhibitor-1 polymorphisms are associated with obesity and fat distribution in the Quebec Family Study: evidence of interactions with menopause. Menopause 2005;12:136-43. DOI |
14 | Salden M, Splinter TA, Peters HA, Look MP, Timmermans M, van Meerbeeck JP, et al. The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. Ann Oncol 2000;11:327-32. DOI |
15 | Offersen BV, Pfeiffer P, Andreasen P, Overgaard J. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis. Lung Cancer 2007;56:43-50. DOI |
16 | Nielsen LS, Andreasen PA, Grondahl-Hansen J, Huang JY, Kristensen P, Dano K. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells: inhibitor neutralization and onestep affinity purification. Thromb Haemost 1986;55:206-12. |
17 | French D, Hamilton LH, Mattano LA Jr, Sather HN, Devidas M, Nachman JB, et al. A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008;111:4496-9. DOI |
18 | Tsai SJ, Hong CJ, Liou YJ, Yu YW, Chen TJ. Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response. Pharmacogenet Genomics 2008;18:869-75. DOI |
19 | Kathiresan S, Gabriel SB, Yang Q, Lochner AL, Larson MG, Levy D, et al. Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels. Circulation 2005;112:1728-35. DOI |
20 | Pedersen H, Grondahl-Hansen J, Francis D, Osterlind K, Hansen HH, Dano K, et al. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 1994;54:120-3. |
21 | Di Bernardo MC, Matakidou A, Eisen T, Houlston RS; GELCAPS Consortium. Plasminogen activator inhibitor variants PAI-1 A15T and PAI-2 S413C influence lung cancer prognosis. Lung Cancer 2009;65:237-41. DOI |
22 | Kutz SM, Higgins CE, Samarakoon R, Higgins SP, Allen RR, Qi L, et al. TGF-beta 1-induced PAI-1 expression is E box/ USF-dependent and requires EGFR signaling. Exp Cell Res 2006;312:1093-105. DOI |
23 | Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. DOI |
24 | Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7. DOI |
25 | Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001;18:1059-68. DOI |
26 | Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-501. DOI |
27 | Samarakoon R, Higgins CE, Higgins SP, Higgins PJ. TGFbeta1- induced expression of the poor prognosis SERPINE1/ PAI-1 gene requires EGFR signaling: a new target for anti- EGFR therapy. J Oncol 2009;2009:342391. |
28 | Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br J Cancer 1999;79:1746-51. DOI |
29 | Duffy MJ, Duggan C. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer. Clin Biochem 2004;37:541-8. DOI |
30 | Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000;60:636-43. |
31 | Heiss MM, Allgayer H, Gruetzner KU, Babic R, Jauch KW, Schildberg FW. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer. Ann Surg 1997;226:736-44. DOI |
32 | Nielsen HJ, Christensen IJ, Sorensen S, Moesgaard F, Brunner N. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol 2000;7:617-23. DOI |
33 | Werle B, Kotzsch M, Lah TT, Kos J, Gabrijelcic-Geiger D, Spiess E, et al. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer. Anticancer Res 2004;24:4147-61. |
34 | Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300. DOI |
35 | Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988;96:440-7. |